Home › Companies › Summit Therapeutics Inc. › 2025-2026

Summit Therapeutics Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Summit Therapeutics Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

12Ballot items
224Asset managers
2,552Fund votes
June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 12 items on Summit Therapeutics Inc.’s Form 8-K, filed June 12, 2026: 12 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Summit Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Summit Therapeutics Inc.

These tallies are Summit Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Summit Therapeutics Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Robert W. Duggan	636,409,964	--	--	10,761,538	30,576,341	98%	Not verified	—
Elect Director: Mahkam Zanganeh	637,405,433	--	--	9,766,069	30,576,341	98%	Not verified	—
Elect Director: Manmeet Soni	636,690,652	--	--	10,480,850	30,576,341	98%	Not verified	—
Elect Director: Kenneth A. Clark	622,127,920	--	--	25,043,582	30,576,341	96%	Not verified	—
Elect Director: Robert Booth	646,257,923	--	--	913,579	30,576,341	99.8%	Not verified	—
Elect Director: Alessandra Cesano	646,263,718	--	--	907,784	30,576,341	99.8%	Not verified	—
Elect Director: Yu (Michelle) Xia	636,028,876	--	--	11,142,626	30,576,341	98%	Not verified	—
Elect Director: Mostafa Ronaghi	646,570,238	--	--	601,264	30,576,341	99.9%	Not verified	—
Elect Director: Jeff Huber	646,659,701	--	--	511,801	30,576,341	99.9%	Not verified	—
Ratification of the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026	677,302,337	85,284	360,222	--	--	99.9%	Not verified	—
Non-binding advisory vote to approve the compensation of named executive officers	622,624,328	24,445,791	101,383	--	30,576,341	96%	Not verified	—
Approval of an amendment to the Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares	619,799,393	27,247,910	124,199	--	30,576,341	96%	Not verified	—

Source: Summit Therapeutics Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the Summit Therapeutics Inc. 2025-2026 meeting

Each item below shows how the 224 asset managers that disclosed a Summit Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Alessandra Cesano

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 646,263,718WITHHELD: 907,784

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Alessandra Cesano

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Alessandra Cesano”): 646,263,718 for, 907,784 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 15,132,325 for, 47,556 withheld, 187 not voted.

FOR

FOR: 15,132,325WITHHOLD: 47,556NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Alessandra Cesano” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Withheld	Vote
T. Rowe Price	6,468,811	0	For
Fidelity	3,965,724	0	For
State Street	1,285,340	474	For
Vanguard	1,229,134	3,878	For
Charles Schwab	938,514	0	For
BlackRock	519,377	0	For
John Hancock	139,502	0	For
ProShares	120,791	0	For
Tema ETF Trust	120,314	0	For
Lincoln Financial	77,100	0	For
Guggenheim	47,079	0	For
Northern Lights Fund Trust IV	31,953	0	For
Equitable	29,087	0	For
SEI	23,900	0	For
TIAA	0	23,195	Withhold
Bridge Builder Trust	22,605	0	For
New York Life	0	20,009	Withhold
Direxion Shares ETF Trust	19,140	0	For
Columbia Threadneedle	11,400	0	For
Venerable Variable Insurance Trust	9,346	0	For
Jackson National	9,207	0	For
Morgan Stanley	9,048	0	For
Voya	8,759	0	For
Goldman Sachs	7,286	0	For
Pacific Life	6,907	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

2. Elect Director: Jeff Huber

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 646,659,701WITHHELD: 511,801

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Jeff Huber

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Jeff Huber”): 646,659,701 for, 511,801 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 15,155,520 for, 24,361 withheld, 187 not voted.

FOR

FOR: 15,155,520WITHHOLD: 24,361NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Jeff Huber” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Withheld	Vote
T. Rowe Price	6,468,811	0	For
Fidelity	3,965,724	0	For
State Street	1,285,340	474	For
Vanguard	1,229,134	3,878	For
Charles Schwab	938,514	0	For
BlackRock	519,377	0	For
John Hancock	139,502	0	For
ProShares	120,791	0	For
Tema ETF Trust	120,314	0	For
Lincoln Financial	77,100	0	For
Guggenheim	47,079	0	For
Northern Lights Fund Trust IV	31,953	0	For
Equitable	29,087	0	For
SEI	23,900	0	For
TIAA	23,195	0	For
Bridge Builder Trust	22,605	0	For
New York Life	0	20,009	Withhold
Direxion Shares ETF Trust	19,140	0	For
Columbia Threadneedle	11,400	0	For
Venerable Variable Insurance Trust	9,346	0	For
Jackson National	9,207	0	For
Morgan Stanley	9,048	0	For
Voya	8,759	0	For
Goldman Sachs	7,286	0	For
Pacific Life	6,907	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

3. Elect Director: Kenneth A. Clark

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 622,127,920WITHHELD: 25,043,582

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Kenneth A. Clark

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Kenneth A. Clark”): 622,127,920 for, 25,043,582 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 3,632,957 for, 11,200,721 withheld, 346,203 abstained, 187 not voted.

FORWITHHOLD

FOR: 3,632,957ABSTAIN: 346,203WITHHOLD: 11,200,721NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Kenneth A. Clark” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
T. Rowe Price	0	0	6,468,811	Withhold
Fidelity	1,909,369	0	2,056,355	Mixed
State Street	2,612	0	1,283,202	Withhold
Vanguard	1,213,428	6	19,578	For
Charles Schwab	1,262	0	937,252	Withhold
BlackRock	338,389	180,988	0	Mixed
John Hancock	0	139,502	0	Abstain
ProShares	0	0	120,791	Withhold
Tema ETF Trust	120,314	0	0	For
Lincoln Financial	0	0	77,100	Withhold
Guggenheim	0	0	47,079	Withhold
Northern Lights Fund Trust IV	31,953	0	0	For
Equitable	0	0	29,087	Withhold
SEI	0	0	23,900	Withhold
TIAA	0	0	23,195	Withhold
Bridge Builder Trust	0	22,605	0	Abstain
New York Life	0	0	20,009	Withhold
Direxion Shares ETF Trust	0	0	19,140	Withhold
Columbia Threadneedle	0	0	11,400	Withhold
Venerable Variable Insurance Trust	0	0	9,346	Withhold
Jackson National	9,207	0	0	For
Morgan Stanley	0	0	9,048	Withhold
Voya	0	0	8,759	Withhold
Goldman Sachs	0	0	7,286	Withhold
Pacific Life	0	0	6,907	Withhold

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

4. Elect Director: Mahkam Zanganeh

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 637,405,433WITHHELD: 9,766,069

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mahkam Zanganeh

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Mahkam Zanganeh”): 637,405,433 for, 9,766,069 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 12,833,471 for, 2,332,209 withheld, 14,200 abstained, 187 not voted.

FORWITHHOLD

FOR: 12,833,471ABSTAIN: 14,200WITHHOLD: 2,332,209NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Mahkam Zanganeh” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
T. Rowe Price	6,468,811	0	0	For
Fidelity	1,909,369	0	2,056,355	Mixed
State Street	1,284,291	0	1,523	For
Vanguard	1,217,311	2	15,700	For
Charles Schwab	938,514	0	0	For
BlackRock	519,377	0	0	For
John Hancock	125,304	14,198	0	Mixed
ProShares	0	0	120,791	Withhold
Tema ETF Trust	120,314	0	0	For
Lincoln Financial	77,100	0	0	For
Guggenheim	0	0	47,079	Withhold
Northern Lights Fund Trust IV	31,953	0	0	For
Equitable	29,087	0	0	For
SEI	23,900	0	0	For
TIAA	0	0	23,195	Withhold
Bridge Builder Trust	22,605	0	0	For
New York Life	0	0	20,009	Withhold
Direxion Shares ETF Trust	0	0	19,140	Withhold
Columbia Threadneedle	11,400	0	0	For
Venerable Variable Insurance Trust	9,346	0	0	For
Jackson National	9,207	0	0	For
Morgan Stanley	0	0	9,048	Withhold
Voya	0	0	8,759	Withhold
Goldman Sachs	7,286	0	0	For
Pacific Life	6,907	0	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

5. Elect Director: Manmeet Soni

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 636,690,652WITHHELD: 10,480,850

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Manmeet S. Soni

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Manmeet Soni”): 636,690,652 for, 10,480,850 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 45 asset managers below reported 12,789,872 for, 2,366,087 withheld, 23,921 abstained, 187 not voted.

FORWITHHOLD

FOR: 12,789,872ABSTAIN: 23,921WITHHOLD: 2,366,087NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Manmeet S. Soni” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
T. Rowe Price	6,468,811	0	0	For
Fidelity	1,909,369	0	2,056,355	Mixed
State Street	1,284,291	0	1,523	For
Vanguard	1,213,432	2	19,578	For
Charles Schwab	938,105	0	410	For
BlackRock	519,377	0	0	For
John Hancock	125,304	14,198	0	Mixed
ProShares	0	0	120,791	Withhold
Tema ETF Trust	120,314	0	0	For
Lincoln Financial	77,100	0	0	For
Guggenheim	0	0	47,079	Withhold
Northern Lights Fund Trust IV	31,953	0	0	For
Equitable	29,087	0	0	For
SEI	0	0	23,900	Withhold
TIAA	0	0	23,195	Withhold
Bridge Builder Trust	22,605	0	0	For
New York Life	0	0	20,009	Withhold
Direxion Shares ETF Trust	0	0	19,140	Withhold
Columbia Threadneedle	11,400	0	0	For
Venerable Variable Insurance Trust	9,346	0	0	For
Jackson National	0	9,207	0	Abstain
Morgan Stanley	0	0	9,048	Withhold
Voya	0	0	8,759	Withhold
Goldman Sachs	7,286	0	0	For
Pacific Life	6,907	0	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

6. Elect Director: Mostafa Ronaghi

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 646,570,238WITHHELD: 601,264

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mostafa Ronaghi

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Mostafa Ronaghi”): 646,570,238 for, 601,264 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 45 asset managers below reported 15,139,175 for, 40,509 withheld, 197 abstained, 187 not voted.

FOR

FOR: 15,139,175ABSTAIN: 197WITHHOLD: 40,509NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Mostafa Ronaghi” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Withheld	Vote
T. Rowe Price	6,468,811	0	For
Fidelity	3,965,724	0	For
State Street	1,285,340	474	For
Vanguard	1,233,013	0	For
Charles Schwab	938,514	0	For
BlackRock	519,377	0	For
John Hancock	139,502	0	For
ProShares	120,791	0	For
Tema ETF Trust	120,314	0	For
Lincoln Financial	77,100	0	For
Guggenheim	47,079	0	For
Northern Lights Fund Trust IV	31,953	0	For
Equitable	16,347	12,740	Mixed
SEI	23,900	0	For
TIAA	23,195	0	For
Bridge Builder Trust	22,605	0	For
New York Life	0	20,009	Withhold
Direxion Shares ETF Trust	19,140	0	For
Columbia Threadneedle	11,400	0	For
Venerable Variable Insurance Trust	9,346	0	For
Jackson National	9,207	0	For
Morgan Stanley	9,048	0	For
Voya	8,759	0	For
Goldman Sachs	0	7,286	Withhold
Pacific Life	6,907	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

7. Elect Director: Robert Booth

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 646,257,923WITHHELD: 913,579

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Robert Booth

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Robert Booth”): 646,257,923 for, 913,579 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 45 asset managers below reported 15,132,325 for, 47,556 withheld, 187 not voted.

FOR

FOR: 15,132,325WITHHOLD: 47,556NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Robert Booth” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Withheld	Vote
T. Rowe Price	6,468,811	0	For
Fidelity	3,965,724	0	For
State Street	1,285,340	474	For
Vanguard	1,229,134	3,878	For
Charles Schwab	938,514	0	For
BlackRock	519,377	0	For
John Hancock	139,502	0	For
ProShares	120,791	0	For
Tema ETF Trust	120,314	0	For
Lincoln Financial	77,100	0	For
Guggenheim	47,079	0	For
Northern Lights Fund Trust IV	31,953	0	For
Equitable	29,087	0	For
SEI	23,900	0	For
TIAA	0	23,195	Withhold
Bridge Builder Trust	22,605	0	For
New York Life	0	20,009	Withhold
Direxion Shares ETF Trust	19,140	0	For
Columbia Threadneedle	11,400	0	For
Venerable Variable Insurance Trust	9,346	0	For
Jackson National	9,207	0	For
Morgan Stanley	9,048	0	For
Voya	8,759	0	For
Goldman Sachs	7,286	0	For
Pacific Life	6,907	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

8. Elect Director: Robert W. Duggan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 636,409,964WITHHELD: 10,761,538

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Robert W. Duggan

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Robert W. Duggan”): 636,409,964 for, 10,761,538 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 45 asset managers below reported 12,833,471 for, 2,332,209 withheld, 14,200 abstained, 187 not voted.

FORWITHHOLD

FOR: 12,833,471ABSTAIN: 14,200WITHHOLD: 2,332,209NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Robert W. Duggan” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
T. Rowe Price	6,468,811	0	0	For
Fidelity	1,909,369	0	2,056,355	Mixed
State Street	1,284,291	0	1,523	For
Vanguard	1,217,311	2	15,700	For
Charles Schwab	938,514	0	0	For
BlackRock	519,377	0	0	For
John Hancock	125,304	14,198	0	Mixed
ProShares	0	0	120,791	Withhold
Tema ETF Trust	120,314	0	0	For
Lincoln Financial	77,100	0	0	For
Guggenheim	0	0	47,079	Withhold
Northern Lights Fund Trust IV	31,953	0	0	For
Equitable	29,087	0	0	For
SEI	23,900	0	0	For
TIAA	0	0	23,195	Withhold
Bridge Builder Trust	22,605	0	0	For
New York Life	0	0	20,009	Withhold
Direxion Shares ETF Trust	0	0	19,140	Withhold
Columbia Threadneedle	11,400	0	0	For
Venerable Variable Insurance Trust	9,346	0	0	For
Jackson National	9,207	0	0	For
Morgan Stanley	0	0	9,048	Withhold
Voya	0	0	8,759	Withhold
Goldman Sachs	7,286	0	0	For
Pacific Life	6,907	0	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

9. Elect Director: Yu (Michelle) Xia

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 636,028,876WITHHELD: 11,142,626

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Yu (Michelle) Xia

Summit Therapeutics Inc.’s own tally for this item (“Elect Director: Yu (Michelle) Xia”): 636,028,876 for, 11,142,626 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 45 asset managers below reported 12,832,913 for, 2,332,766 withheld, 14,201 abstained, 187 not voted.

FORWITHHOLD

FOR: 12,832,913ABSTAIN: 14,201WITHHOLD: 2,332,766NOT VOTED: 187

Largest asset managers voting on “ELECTION OF DIRECTORS: Yu (Michelle) Xia” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
T. Rowe Price	6,468,811	0	0	For
Fidelity	1,909,369	0	2,056,355	Mixed
State Street	1,284,291	0	1,523	For
Vanguard	1,217,310	3	15,700	For
Charles Schwab	938,514	0	0	For
BlackRock	519,377	0	0	For
John Hancock	125,304	14,198	0	Mixed
ProShares	0	0	120,791	Withhold
Tema ETF Trust	120,314	0	0	For
Lincoln Financial	77,100	0	0	For
Guggenheim	0	0	47,079	Withhold
Northern Lights Fund Trust IV	31,953	0	0	For
Equitable	29,087	0	0	For
SEI	23,900	0	0	For
TIAA	0	0	23,195	Withhold
Bridge Builder Trust	22,605	0	0	For
New York Life	0	0	20,009	Withhold
Direxion Shares ETF Trust	0	0	19,140	Withhold
Columbia Threadneedle	11,400	0	0	For
Venerable Variable Insurance Trust	9,346	0	0	For
Jackson National	9,207	0	0	For
Morgan Stanley	0	0	9,048	Withhold
Voya	0	0	8,759	Withhold
Goldman Sachs	7,286	0	0	For
Pacific Life	6,907	0	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

10. Approval of an amendment to the Plan to increase the number of shares of the Company's common stock issuable under the…

Outcome not verifiedCOMPENSATIONReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 619,799,393AGAINST: 27,247,910

Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock.

Summit Therapeutics Inc.’s own tally for this item (“Approval of an amendment to the Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares”): 619,799,393 for, 27,247,910 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 1,801,287 for, 13,382,533 against, 187 not voted.

AGAINST

FOR: 1,801,287AGAINST: 13,382,533NOT VOTED: 187

Largest asset managers voting on “Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of S” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	0	6,468,811	Against
Fidelity	7,725	3,957,999	Against
State Street	1,282,255	3,559	For
Vanguard	4,564	1,228,449	Against
Charles Schwab	1,262	937,252	Against
BlackRock	338,389	180,988	Mixed
John Hancock	0	139,502	Against
ProShares	0	120,791	Against
Tema ETF Trust	120,314	0	For
Lincoln Financial	0	77,100	Against
Guggenheim	0	47,079	Against
Northern Lights Fund Trust IV	31,953	0	For
Equitable	0	29,087	Against
SEI	0	23,900	Against
TIAA	0	23,195	Against
Bridge Builder Trust	0	22,605	Against
New York Life	0	20,009	Against
Direxion Shares ETF Trust	0	19,140	Against
Columbia Threadneedle	0	11,400	Against
Venerable Variable Insurance Trust	0	9,346	Against
Jackson National	9,207	0	For
Morgan Stanley	0	9,048	Against
Voya	0	8,759	Against
Goldman Sachs	0	7,286	Against
Pacific Life	0	6,907	Against

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

11. Non-binding advisory vote to approve the compensation of named executive officers

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 622,624,328AGAINST: 24,445,791

Details: description as filed, official tally, votes by 224 asset managers

Description as filed by funds: Approval, by a non-binding advisory vote, of the compensation of our named executive officers.

Summit Therapeutics Inc.’s own tally for this item (“Non-binding advisory vote to approve the compensation of named executive officers”): 622,624,328 for, 24,445,791 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 45 asset managers voting on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	0	6,468,811	Against
Fidelity	2,034,655	1,931,069	Mixed
State Street	2,612	1,283,202	Against
Vanguard	11,363	1,221,649	Against
Charles Schwab	1,262	937,252	Against
BlackRock	0	519,377	Against
John Hancock	0	139,502	Against
ProShares	0	120,791	Against
Tema ETF Trust	120,314	0	For
Lincoln Financial	0	77,100	Against
Guggenheim	0	47,079	Against
Northern Lights Fund Trust IV	31,953	0	For
Equitable	0	29,087	Against
SEI	0	23,900	Against
TIAA	23,195	0	For
Bridge Builder Trust	0	22,605	Against
New York Life	0	20,009	Against
Direxion Shares ETF Trust	0	19,140	Against
Columbia Threadneedle	0	11,400	Against
Venerable Variable Insurance Trust	0	9,346	Against
Jackson National	0	9,207	Against
Morgan Stanley	0	9,048	Against
Voya	0	8,759	Against
Goldman Sachs	0	7,286	Against
Pacific Life	0	6,907	Against

Fund voting reports, all 45 managers: 2,227,833 for, 12,952,048 against, 187 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 188 asset managers voting on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	0	7,825,505	Against
Fidelity	5,623,989	345	For
BlackRock	11,995	2,200,151	Against
GEODE CAPITAL MANAGEMENT, LLC	0	2,079,711	Against
State Street	2,660	2,000,520	Against
PICTET ASSET MANAGEMENT SA	0	1,488,970	Against
DE Shaw	0	1,290,545	Against
Charles Schwab	1,262	941,495	Against
Aberdeen	0	665,364	Against
Candriam S.C.A.	0	540,662	Against
Wellington	0	360,887	Against
Northern Trust	0	258,579	Against
Allianz	0	246,280	Against
GRIFFIN ASSET MANAGEMENT, INC.	0	190,163	Against
Woodline Partners LP	182,023	0	For
BANK OF AMERICA NA	0	181,495	Against
Invesco	0	129,534	Against
ADAR1 Capital Management, LLC	0	88,900	Against
WELLS FARGO CLEARING SERVICES, LLC	87,947	0	For
MELLON INVESTMENTS Corp	0	82,527	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	74,248	Against
SECTORAL ASSET MANAGEMENT INC	0	69,500	Against
Vanguard	0	69,153	Against
BNY Mellon	0	68,550	Against
CANADA PENSION PLAN INVESTMENT BOARD	0	65,400	Against

Institutional-manager reports, all 188 managers: 6,082,591 for, 21,665,631 against, 109 abstained, 1,203 not voted. Showing the 25 largest; see all in the interactive database.

12. Ratification of the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 677,302,337AGAINST: 85,284

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026.

Summit Therapeutics Inc.’s own tally for this item (“Ratification of the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026”): 677,302,337 for, 85,284 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 15,180,881 for, 187 not voted.

FOR

FOR: 15,180,881NOT VOTED: 187

Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm” at Summit Therapeutics Inc., 2025-2026
Asset manager	For	Vote
T. Rowe Price	6,468,811	For
Fidelity	3,965,724	For
State Street	1,285,814	For
Vanguard	1,233,013	For
Charles Schwab	938,514	For
BlackRock	519,377	For
John Hancock	139,502	For
ProShares	120,791	For
Tema ETF Trust	120,314	For
Lincoln Financial	77,100	For
Guggenheim	47,079	For
Northern Lights Fund Trust IV	31,953	For
Equitable	29,087	For
SEI	23,900	For
TIAA	23,195	For
Bridge Builder Trust	22,605	For
New York Life	20,009	For
Direxion Shares ETF Trust	19,140	For
Columbia Threadneedle	11,400	For
Venerable Variable Insurance Trust	9,346	For
Jackson National	9,207	For
Morgan Stanley	9,048	For
Voya	8,759	For
Goldman Sachs	7,286	For
Pacific Life	6,907	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Largest Summit Therapeutics Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 776,017,474 shares outstanding at the time of that meeting.

Fund voting reports: top Summit Therapeutics Inc. shareholders by shares voted on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.”, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	0.83%
2	Fidelity	0.51%
3	State Street	0.17%
4	Vanguard	0.16%
5	Charles Schwab	0.12%
6	BlackRock	0.07%
7	John Hancock	0.02%
8	ProShares	0.02%
9	Tema ETF Trust	0.02%
10	Lincoln Financial	<0.01%

Institutional-manager reports: top Summit Therapeutics Inc. shareholders by shares voted on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.”, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	1.01%
2	Fidelity	0.72%
3	BlackRock	0.29%
4	GEODE CAPITAL MANAGEMENT, LLC	0.27%
5	State Street	0.26%
6	PICTET ASSET MANAGEMENT SA	0.19%
7	DE Shaw	0.17%
8	Charles Schwab	0.12%
9	Aberdeen	0.09%
10	Candriam S.C.A.	0.07%

Reported Summit Therapeutics Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Summit Therapeutics Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Robert W. Duggan	73.46%	DEF14A
Mahkam Zanganeh	4.64%	DEF14A
Yu (Michelle) Xia	4.13%	DEF14A
Vanguard Group	1.44%	13F
FMR (Fidelity)	1.40%	13F
BlackRock	1.24%	13F
T. Rowe Price	1.07%	13F
State Street	0.91%	13F
Geode Capital	0.43%	13F
Manmeet Soni	0.40%	DEF14A

Percentages above are of 776,017,474 shares outstanding, as reported by Summit Therapeutics Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Summit Therapeutics Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Summit Therapeutics Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 224 asset managers reported how they voted on 12 ballot items in their SEC Form N-PX filings, covering 2,552 separate fund positions. On the most widely held item on that ballot — Approval, by a non-binding advisory vote, of the compensation of our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Summit Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

Summit Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.